Leadscope, Inc.

Columbus, OH 43215

SBIR Award Summary

Total Number of Awards 4
Total Value of Awards $499K
First Award Date 05/01/02
Most Recent Award Date 06/01/16

Key Personnel

Last Name Name Awards Contact
Yang Chihae Yang 2
MYATT GLENN JOHN MYATT 2

4 Awards Won

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PA-15-269
Budget: 06/01/16 - 11/30/16

? DESCRIPTION (provided by applicant): In many situations, it is critical to rapidly estimate the safety of new or existing chemicals. For example, in the event of a sudden unexpected exposure of a chemical, such as with a chemical spill or a terrorist attack, an emergency response is needed to determine if and how to mitigate any potential ri...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PA-13-234
Budget: 06/03/14 - 05/31/15

DESCRIPTION (provided by applicant): The field of green chemistry was established in order to reduce or even eliminate any negative impact from the introduction of new chemical products such as new pesticides, cosmetics, or drugs to human health or the environment. Unfortunately, current approaches for testing chemicals are expensive, time-consu...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PAR-01-105
Budget: 05/01/03 - 04/30/04

"Gene-to-drug" is a new paradigm in drug discovery based on the novel methodology of chemical genomics. This approach provides a means to systematically analyze the vast quantities of genomics information generated by high throughput experiments to develop new pharmacophores. The methodology seeks to match biological targets and drug candidates ...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PAR-01-105
Budget: 05/01/02 - 04/30/03

"Gene-to-drug" is a new paradigm in drug discovery based on the novel methodology of chemical genomics. This approach provides a means to systematically analyze the vast quantities of genomics information generated by high throughput experiments to develop new pharmacophores. The methodology seeks to match biological targets and drug candidates ...